Ageing - Pipeline Review, H2 2016

Global Markets Direct’s, ‘Ageing - Pipeline Review, H2 2016’, provides an overview of the Ageing pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ageing, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ageing and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Ageing

The report reviews pipeline therapeutics for Ageing by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Ageing therapeutics and enlists all their major and minor projects

The report assesses Ageing therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Ageing

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Ageing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Ageing pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Generon (Shanghai) Corporation Ltd.

Mapreg S.A.S.

RepliCel Life Sciences, Inc.

RXi Pharmaceuticals Corporation

Saje Pharma, LLC

Theravasc, Inc.

Generon (Shanghai) Corporation Ltd.

Mapreg S.A.S.

RepliCel Life Sciences, Inc.

RXi Pharmaceuticals Corporation

Saje Pharma, LLC

Theravasc, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Ageing Overview ...

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Ageing Overview 7

Therapeutics Development 8

Pipeline Products for Ageing - Overview 8

Pipeline Products for Ageing - Comparative Analysis 9

Ageing - Therapeutics under Development by Companies 10

Ageing - Therapeutics under Investigation by Universities/Institutes 11

Ageing - Pipeline Products Glance 12

Clinical Stage Products 12

Early Stage Products 13

Ageing - Products under Development by Companies 14

Ageing - Products under Investigation by Universities/Institutes 15

Ageing - Companies Involved in Therapeutics Development 16

Generon (Shanghai) Corporation Ltd. 16

Mapreg S.A.S. 17

RepliCel Life Sciences, Inc. 18

RXi Pharmaceuticals Corporation 19

Saje Pharma, LLC 20

Theravasc, Inc. 21

Ageing - Therapeutics Assessment 22

Assessment by Monotherapy Products 22

Assessment by Target 23

Assessment by Mechanism of Action 25

Assessment by Route of Administration 27

Assessment by Molecule Type 29

Drug Profiles 31

AGS-499 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

BQ-A - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Drugs for Ageing - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

F-899 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

MAP-46 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

MG-29 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

MMP-26051 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

MMP-26052 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

RCS-01 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

sirolimus - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

sodium nitrite SR - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

SPL-891.1 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

TM-5441 - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

Ageing - Dormant Projects 46

Ageing - Product Development Milestones 47

Featured News & Press Releases 47

Apr 20, 2016: RepliCel Life Sciences Finishes Enrolment for its Skin Rejuvenation Clinical Trial 47

Dec 17, 2015: RepliCel Announces Completion of First Injections in Clinical Trial of RCS-01 for Skin Aging and UV-Damaged Skin 47

Sep 15, 2015: RepliCel Life Sciences Announces Initiation of Clinical Site and Participant Recruitment for European Skin Aging Study 48

Jul 21, 2015: RepliCel Receives Two Important Approvals for Dermal Rejuvenation Clinical Trial 49

Feb 23, 2015: RepliCel Submits Clinical Trial Application for its Dermatological Clinical Trial 50

Oct 09, 2014: RepliCel to Present Commercial and Clinical Update on RCS-01 at BioJapan 2014 World Business Forum 51

Appendix 52

Methodology 52

Coverage 52

Secondary Research 52

Primary Research 52

Expert Panel Validation 52

Contact Us 52

Disclaimer 53

List of Tables

List of Tables

Number of Products under Development for Ageing, H2 2016 8

Number of Products under Development for Ageing - Comparative Analysis, H2 2016 9 ...

List of Tables

Number of Products under Development for Ageing, H2 2016 8

Number of Products under Development for Ageing - Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 12

Comparative Analysis by Early Stage Development, H2 2016 13

Products under Development by Companies, H2 2016 14

Products under Investigation by Universities/Institutes, H2 2016 15

Ageing - Pipeline by Generon (Shanghai) Corporation Ltd., H2 2016 16

Ageing - Pipeline by Mapreg S.A.S., H2 2016 17

Ageing - Pipeline by RepliCel Life Sciences, Inc., H2 2016 18

Ageing - Pipeline by RXi Pharmaceuticals Corporation, H2 2016 19

Ageing - Pipeline by Saje Pharma, LLC, H2 2016 20

Ageing - Pipeline by Theravasc, Inc., H2 2016 21

Assessment by Monotherapy Products, H2 2016 22

Number of Products by Stage and Target, H2 2016 24

Number of Products by Stage and Mechanism of Action, H2 2016 26

Number of Products by Stage and Route of Administration, H2 2016 28

Number of Products by Stage and Molecule Type, H2 2016 30

Ageing - Dormant Projects, H2 2016 46

List of Figures

List of Figures

Number of Products under Development for Ageing, H2 2016 8

Number of Products under Development for Ageing - Comparative Analysis, H2 2016 9 ...

List of Figures

Number of Products under Development for Ageing, H2 2016 8

Number of Products under Development for Ageing - Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy Products, H2 2016 22

Number of Products by Targets, H2 2016 23

Number of Products by Stage and Targets, H2 2016 23

Number of Products by Mechanism of Actions, H2 2016 25

Number of Products by Stage and Mechanism of Actions, H2 2016 25

Number of Products by Routes of Administration, H2 2016 27

Number of Products by Stage and Routes of Administration, H2 2016 27

Number of Products by Molecule Types, H2 2016 29

Number of Products by Stage and Molecule Types, H2 2016 29

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports